SutroVax: Upscaled antigens
Sutro spinout SutroVax unlocks scaled-up manufacture of hard-to-make vaccines
SutroVax Inc. spun out of Sutro Biopharma Inc. to capitalize on the scalability of Sutro's Xpress CF cell-free protein synthesis platform in the production of vaccine antigens. Comparable technologies produce protein only in minute amounts, according to SutroVax, but its system has been industrialized under cGMP conditions and scaled to multiple 100 L vessels.
Protein synthesis is conventionally carried out using cell-based expression systems such as bacteria, yeast, or mammalian cell culture. Sutro Biopharma developed its platform based on functional extracts of cellular components that carry out all of the biochemical functions necessary for protein production. That includes not only transcription and translation from a DNA sequence, but also energy production through oxidative phosphorylation...